Zacks Investment Research upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a sell rating to a hold rating in a report published on Tuesday.
According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
GTHX has been the topic of several other reports. Wedbush restated an outperform rating and set a $67.00 target price on shares of G1 Therapeutics in a report on Thursday, December 20th. Raymond James began coverage on shares of G1 Therapeutics in a report on Wednesday, December 19th. They set a strong-buy rating on the stock. BidaskClub downgraded shares of G1 Therapeutics from a hold rating to a sell rating in a report on Tuesday, December 18th. Cowen restated a buy rating on shares of G1 Therapeutics in a report on Wednesday, March 6th. Finally, B. Riley began coverage on shares of G1 Therapeutics in a report on Thursday, February 7th. They set a buy rating and a $55.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $66.00.
In other G1 Therapeutics news, Director Cynthia Schwalm purchased 1,420 shares of the firm’s stock in a transaction dated Wednesday, December 26th. The stock was bought at an average cost of $18.45 per share, with a total value of $26,199.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Rajesh Malik sold 3,776 shares of the firm’s stock in a transaction that occurred on Monday, December 17th. The stock was sold at an average price of $30.00, for a total transaction of $113,280.00. The disclosure for this sale can be found here. Company insiders own 15.92% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. bought a new position in shares of G1 Therapeutics during the 3rd quarter worth approximately $111,000. Legal & General Group Plc grew its stake in shares of G1 Therapeutics by 20.0% during the 4th quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock worth $78,000 after acquiring an additional 676 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of G1 Therapeutics during the 3rd quarter worth approximately $218,000. Meeder Asset Management Inc. grew its stake in shares of G1 Therapeutics by 147.7% during the 4th quarter. Meeder Asset Management Inc. now owns 4,484 shares of the company’s stock worth $87,000 after acquiring an additional 2,674 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of G1 Therapeutics during the 3rd quarter worth approximately $243,000. 75.08% of the stock is owned by institutional investors.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Featured Story: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.